Mechanism-of-Action Support in Inflammatory Lung Disease
Therapeutic development programs often have strong preclinical rationale but limited direct evidence of how a candidate therapy affects human disease biology. Demonstrating biological activity, identifying translational biomarkers, and understanding patient-level response remain major challenges in clinical development.
Human biology-driven validation of therapeutic hypotheses.
APPROACH
Stratica applied single-cell genomics, computational immune profiling, and biological intelligence modeling to longitudinal blood samples collected during a clinical study in inflammatory lung disease. Using StraticaOS, the team constructed high-resolution immune atlases and evaluated treatment-associated biological changes across patient-derived immune cells.
The analysis was designed to determine whether human cellular response patterns were consistent with the therapeutic hypothesis and to identify biomarker signatures that could support future clinical development.
KEY OUTCOMES
Built a longitudinal single-cell immune atlas from clinical study samples
Identified treatment-associated changes in immune cell states and inflammatory programs
Generated biological evidence consistent with the proposed therapeutic mechanism
Identified candidate translational biomarkers for future study design
Supported expansion of the clinical development program through deeper biological insight
Established a framework for integrating single-cell immune profiling into therapeutic de-risking
IMPACT
This program demonstrates how biological intelligence can help therapeutic developers move beyond clinical endpoints alone. By measuring how candidate therapies affect patient-derived cellular systems, Stratica helps partners evaluate mechanism-of-action support, discover translational biomarkers, understand response biology, and inform future clinical development decisions.
APPLICATIONS
Precision Therapeutic Evaluation in Advanced Fibrotic Lung Disease
Ready to build the next case study?
Stratica helps partners move from complex human biology to actionable therapeutic insight.